CA Patent

CA2820245A1 — Dosage and administration for preventing cardiotoxicity in treatment with erbb2-targeted immunoliposomes comprising anthracycline chemotherapeutic agents

Assigned to Merrimack Pharmaceuticals Inc · Expires 2012-06-14 · 14y expired

What this patent protects

Patent listed against Camptosar.

Drugs covered by this patent

Patent Metadata

Patent number
CA2820245A1
Jurisdiction
CA
Classification
—
Expires
2012-06-14
Drug substance claim
No
Drug product claim
No
Assignee
Merrimack Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.